Arcutis Biotherapeutics sets up $200 million at-the-market stock offering
The dermatology company filed a prospectus supplement on November 4, 2026 allowing it to sell up to $200 million of common stock through TD Cowen over time.
SEC filing
4 stories
The dermatology company filed a prospectus supplement on November 4, 2026 allowing it to sell up to $200 million of common stock through TD Cowen over time.
SEC filing
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The commercial-stage dermatology company added the former AbbVie chief medical officer effective October 23, 2026, expanding its board to eleven members.
SEC filing